In MS patients, peripheral blood mononuclear cells (PBMC) exhibit decreased PPARγ expression inversely correlated with disease activity and PPARγ agonists may have beneficial effects [4–6]. The gene discussed is PPARG; the disease is myeloid sarcoma.